Abstract:Acute myeloid leukemia (AML) is the second most common adult leukemia with a five-year survival rate around 30%. For decades, AML treatment has centered around intensive chemotherapy frequently followed by allogeneic stem cell transplant (Allo-SCT). The power of Allo-SCT to induce lasting remission has been attributed to a potent graft-versus-leukemia effect and has inspired efforts to stimulate host immunity against AML via immune checkpoint blockade (ICB). Thus far, these studies have yielded mixed results. While tumor-infiltrating T-cells have long been the focus of immunotherapy investigations, a growing body of data points to a central role of B-cells in mediating anti-tumor immunity, and a comprehensive assessment of B lymphocytes within the AML immune microenvironment has never been carried out with single cell clonal resolution. We performed paired single-cell transcriptomic and B cell receptor (BCR) analysis on 52 bone marrow aspirate samples. These samples included 6 from healthy bone marrow donors (normal), 24 from newly diagnosed AML patients (NewlyDx), and 22 from 8 relapsed or refractory AML patients (RelRef), who underwent assessment both before and after ICB with azacitidine/nivolumab. We first used transcriptomic data to delineate canonical B-cell subpopulations and observed a reduction in nascent B cells and an expansion of differentiated B cells in AML patients (RelRef>NewlyDx). Overlaying BCR sequencing and clonotypic analysis revealed clonal expansion, low clonotypic diversity, and extensive somatic hypermutation in the RelRef samples, suggesting antigen-driven affinity maturation within the tumor microenvironment. Furthermore, we identified robust AP-1 expression (a marker of activation) in B-cells from NewlyDx patients and a marked loss of AP-1 in RelRef patients, suggesting that B-cell exhaustion may be a key immunologic feature of AML relapse. Importantly, we observed that AP-1 activity is restored and that specific B-cell clones expand after ICB, but only among patients who clinically respond to ICB. In line with these observations, we also noted the clonal expansion of AML-associated plasma cells and loss of clonotypic diversity among ICB clinical responders, pointing to an antitumor role for these clones. Finally, we characterized atypical memory B cells which demonstrate high antigen presentation activity, close interaction with AML cells and are associated with unfavorable clinical outcomes, suggesting that they play a direct role in aiding AML survival and immune escape. Collectively, our findings establish the dynamic landscape of AML-associated B-cells while identifying specific B-cell subpopulations and B-cell-AML interactions that may be targeted by the next generation of AML-directed immunotherapies. Citation Format: Shengnan Guo, Gopi S. Mohan, Bofei Wang, Tianhao Li, Naval Daver, Yuting Zhao, Patrick K. Reville, Dapeng Hao, Hussein A. Abbas. Paired single-cell B-cell transcriptomics and receptor sequencing reveal activation states and clonal signatures that characterize B cell immunity in acute myeloid leukemia [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 6869.

Expression Of Immunoglobulin Gene In Myeloblasts From Patients With Acute Myelogenous Leukemia And Its Distinct V(K)J(K) Recombination Pattern

Rearrangement and Expression of the Immunoglobulin Μ-Chain Gene in Human Myeloid Cells

Next-Generation Sequencing Revealed a Distinct Immunoglobulin Repertoire with Specific Mutation Hotspots in Acute Myeloid Leukemia

Levels and Clinical Significance of Regulatory B Cells and T Cells in Acute Myeloid Leukemia

MicroRNA Expression Profiles in Acute Myeloid Leukemia with Common Translocations.

Significance of Clonal Gene Rearrangements of Immunoglobulin Heavy Chain and T-cell Receptor Γ in Acute Nonlymphoblastic Leukemia

Immunoglobulin Gamma Heavy Chain Gene with Somatic Hypermutation is Frequently Expressed in Acute Myeloid Leukemia.

High Levels of Immunoglobulin Expression Predict Shorter Overall Survival in Patients with Acute Myeloid Leukemia

Aberration Antigen Expression in Adult Acute Myelocytic Leukemias

IGK with conserved IGΚV/IGΚJ repertoire is expressed in acute myeloid leukemia and promotes leukemic cell migration

Distinct Microrna Expression Profiles In Acute Myeloid Leukemia With Common Translocations

Profiling of Micrornas in Aml Cells Following Overexpression or Silencing of the Vegf Gene

[The Role of MPO Mrna, IgH Mrna and CD3epsilon Mrna Expressions in Classification of Acute Leukemias].

The Clinical Impact of IKZF1 Mutation in Acute Myeloid Leukemia

Expression, Function, and Significance of Non B Cell-Derived Immunoglobulin in Haematological System

Expression and Clinical Significance of ID1 Gene in Acute Myeloid Leukemia

A Comparative Analysis of the Immunoglobulin Repertoire in Leukemia Cells and B Cells in Chinese Acute Myeloid Leukemia by High-Throughput Sequencing

Abstract #LB-142: Immunoglobulin Gene Transcripts from Human Epithelial Cancer Cells Have Distinct VHDJH or VKJK Recombination

Immunoglobulin Expression in Non-Lymphoid Lineage and Neoplastic Cells

Abstract 6869: Paired single-cell B-cell transcriptomics and receptor sequencing reveal activation states and clonal signatures that characterize B cell immunity in acute myeloid leukemia

Immunoglobulin Gene Transcripts Have Distinct VHDJH Recombination Characteristics in Human Epithelial Cancer Cells*